The new era of precision medicine in hepatocellular carcinoma: the urgent need for promising biomarkers

Haruhiko Takeda^{1

2}, Hiroki Nishikawa^{2

3}, Yukio Osaki^{2

4}

Affiliations

¹ Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
² Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
³ Department of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
⁴ Department of Gastroenterology and Hepatology, Meiwa Hospital, Nishinomiya, Japan.

Editorial

Haruhiko Takeda et al. Hepatobiliary Surg Nutr. 2018 Dec.

. 2018 Dec;7(6):490-491.

doi: 10.21037/hbsn.2018.08.06.

Haruhiko Takeda^{1

2}, Hiroki Nishikawa^{2

3}, Yukio Osaki^{2

4}

¹ Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
² Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
³ Department of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
⁴ Department of Gastroenterology and Hepatology, Meiwa Hospital, Nishinomiya, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Kudo M, et al. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. Lancet. 2018. PMID: 29433850 Clinical Trial.

1. Kudo M. A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib. Liver Cancer 2017;6:177-84. 10.1159/000462153 - DOI - PMC - PubMed
1. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. 10.1016/S0140-6736(18)30207-1 - DOI - PubMed
1. Ikeda M, Kudo M, Kobayashi M, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol 2018;36:abstr 4076.
1. Peck-Radosavljevic M, Kudo M, Raoul JL, et al. Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis. J Clin Oncol 2018;36:abstr 4018.
1. Arao T, Ueshima K, Matsumoto K, et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 2013;57:1407-15. 10.1002/hep.25956 - DOI - PubMed